1. pregnancy or breast feeding; 2. alt and/or ast \> 5 x uln 3. known, active auto-immune disease; 4. patients with a history of lymphoid malignancy 5. patients with any malignancy that is present at time of enrollment where treating physician expects life expectancy due to the underlying malignancy to be less than 6 months 6. patients who received car-t cell therapy within the past 30 days or with unresolved cytokine release syndrome (crs) or immune effector cell-associated neurotoxicity syndrome (icans) 7. patients with unresolved grade \> 2 toxicities from prior chemotherapy, immunotherapy, or car-t cell therapy 8. patients with past history of solid organ transplant. 9. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load. 10. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation \>85% with maximal available therapy for \>6 hours 11. patients with a mechanical ventilation support ≥ 7 days 12. patients with chronic kidney dialysis 13. patients with a sofa score ≥ 9 at baseline 14. patients with a bmi \> 40 15. patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) 16. patients with hospital admission rockwood clinical frailty scale ≥ 6. (assessed as patient or proxy 4-week recall of chronic health and frailty status prior to covid infection) 11. patients under guardianship

1. pregnancy or breast feeding; 2. alt and/or ast \> 5 x uln 3. known, active auto-immune disease; 4. patients with a history of lymphoid malignancy 5. patients with any malignancy that is present at time of enrollment where treating physician expects life expectancy due to the underlying malignancy to be less than 6 months 6. patients who received car-t cell therapy within the past 30 days or with unresolved cytokine release syndrome (crs) or immune effector cell-associated neurotoxicity syndrome (icans) 7. patients with unresolved grade \> 2 toxicities from prior chemotherapy, immunotherapy, or car-t cell therapy 8. patients with past history of solid organ transplant. 9. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load. 10. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation \>85% with maximal available therapy for \>6 hours 11. patients with a mechanical ventilation support ≥ 7 days 12. patients with chronic kidney dialysis 13. patients with a sofa score ≥ 9 at baseline 14. patients with a bmi \> 40 15. patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) 16. patients with hospital admission rockwood clinical frailty scale ≥ 6. (assessed as patient or proxy 4-week recall of chronic health and frailty status prior to covid infection) 11. patients under guardianship

pregnancy or breast feeding; alt and/or ast > 5 x uln known, active auto-immune disease; patients with a history of lymphoid malignancy patients with any malignancy that is present at time of enrollment where treating physician expects life expectancy due to the underlying malignancy to be less than 6 months patients who received car-t cell therapy within the past 30 days or with unresolved cytokine release syndrome (crs) or immune effector cell-associated neurotoxicity syndrome (icans) patients with unresolved grade > 2 toxicities from prior chemotherapy, immunotherapy, or car-t cell therapy patients with past history of solid organ transplant. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours patients with a mechanical ventilation support ≥ 7 days patients with chronic kidney dialysis patients with a sofa score ≥ 9 at baseline patients with a bmi > 40 patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) patients with hospital admission rockwood clinical frailty scale ≥ 6. (assessed as patient or proxy 4-week recall of chronic health and frailty status prior to covid infection) 11. patients under guardianship

pregnancy or breast feeding; alt and/or ast > 5 x uln known, active auto-immune disease; patients with a history of lymphoid malignancy patients with any malignancy that is present at time of enrollment where treating physician expects life expectancy due to the underlying malignancy to be less than 6 months patients who received car-t cell therapy within the past 30 days or with unresolved cytokine release syndrome (crs) or immune effector cell-associated neurotoxicity syndrome (icans) patients with unresolved grade > 2 toxicities from prior chemotherapy, immunotherapy, or car-t cell therapy patients with past history of solid organ transplant. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours patients with a mechanical ventilation support ≥ 7 days patients with chronic kidney dialysis patients with a sofa score ≥ 9 at baseline patients with a bmi > 40 patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) patients with hospital admission rockwood clinical frailty scale ≥ 6. (assessed as patient or proxy 4-week recall of chronic health and frailty status prior to covid infection) 11. patients under guardianship

1. pregnancy or breast feeding; 2. alt and/or ast > 5 x uln 3. known, active auto-immune disease; 4. patients with a history of lymphoid malignancy 5. patients with any malignancy that is present at time of enrollment where treating physician expects life expectancy due to the underlying malignancy to be less than 6 months 6. patients who received car-t cell therapy within the past 30 days or with unresolved cytokine release syndrome (crs) or immune effector cell-associated neurotoxicity syndrome (icans) 7. patients with unresolved grade > 2 toxicities from prior chemotherapy, immunotherapy, or car-t cell therapy 8. patients with past history of solid organ transplant. 9. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load. 10. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours 11. patients with a mechanical ventilation support ≥ 7 days 12. patients with chronic kidney dialysis 13. patients with a sofa score ≥ 9 at baseline 14. patients with a bmi > 40 15. patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) 16. patients with hospital admission rockwood clinical frailty scale ≥ 6. (assessed as patient or proxy 4-week recall of chronic health and frailty status prior to covid infection) 11. patients under guardianship

1. pregnancy or breast feeding; 2. alt and/or ast > 5 x uln 3. known, active auto-immune disease; 4. patients with a history of lymphoid malignancy 5. patients with any malignancy that is present at time of enrollment where treating physician expects life expectancy due to the underlying malignancy to be less than 6 months 6. patients who received car-t cell therapy within the past 30 days or with unresolved cytokine release syndrome (crs) or immune effector cell-associated neurotoxicity syndrome (icans) 7. patients with unresolved grade > 2 toxicities from prior chemotherapy, immunotherapy, or car-t cell therapy 8. patients with past history of solid organ transplant. 9. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load. 10. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours 11. patients with a mechanical ventilation support ≥ 7 days 12. patients with chronic kidney dialysis 13. patients with a sofa score ≥ 9 at baseline 14. patients with a bmi > 40 15. patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) 16. patients with hospital admission rockwood clinical frailty scale ≥ 6. (assessed as patient or proxy 4-week recall of chronic health and frailty status prior to covid infection) 11. patients under guardianship

1. pregnancy or breast feeding; 2. alt and/or ast > 5 x uln 3. known, active auto-immune disease; 4. patients with a history of lymphoid malignancy 5. patients with any malignancy that is present at time of enrollment where treating physician expects life expectancy due to the underlying malignancy to be less than 6 months 6. patients with past history of solid organ transplant. 7. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load. 8. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours 9. patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300mg/day and/or anti-il6 treatments like tocilizumab or sarilumab which should preferably be minimized 10. patients with hospital admission rockwood clinical frailty scale ≥ 6. 11. patients under guardianship

1. pregnancy or breast feeding; 2. alt and/or ast > 5 x uln 3. known, active auto-immune disease; 4. patients with a history of lymphoid malignancy 5. patients with any malignancy that is present at time of enrollment where treating physician expects life expectancy due to the underlying malignancy to be less than 6 months 6. patients with past history of solid organ transplant. 7. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load. 8. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours 9. patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300mg/day and/or anti-il6 treatments like tocilizumab or sarilumab which should preferably be minimized 10. patients with hospital admission rockwood clinical frailty scale ≥ 6. 11. patients under guardianship